Investment Management Corp of Ontario grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 49.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 225,879 shares of the company’s stock after buying an additional 74,454 shares during the quarter. Johnson & Johnson accounts for approximately 0.6% of Investment Management Corp of Ontario’s portfolio, making the stock its 19th biggest position. Investment Management Corp of Ontario’s holdings in Johnson & Johnson were worth $46,746,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Blueline Advisors LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $25,000. Cresta Advisors Ltd. purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $26,000. DecisionPoint Financial LLC boosted its stake in shares of Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after buying an additional 75 shares during the period. Bay Harbor Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after buying an additional 49 shares during the period. Finally, Family CFO Inc purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Trading Down 0.7%
JNJ opened at $233.44 on Thursday. The firm has a market cap of $561.95 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 2.30 and a beta of 0.26. Johnson & Johnson has a 52 week low of $149.04 and a 52 week high of $251.71. The business’s 50 day moving average is $231.07 and its two-hundred day moving average is $227.93. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.3%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is presently 61.97%.
Johnson & Johnson Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
